Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: JW0104+C2402, JW0104+C2403, C2402.
- Who it may be relevant to
- Registry conditions: Hypertension, Dyslipidemia. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
Overview
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia
Detailed description
To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.
Interventions
- Drug JW0104+C2402
For 8 weeks(PO (Per Oral), QD) - Drug JW0104+C2403
For 8 weeks(PO, QD) - Drug C2402
For 8 weeks(PO, QD)
Primary outcome measures
- Change from baseline in msSBP (Systolic Blood Pressure) [Time frame: week 8]
- Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol) [Time frame: week 8]
Secondary outcome measures (2)
- change from baseline in msSBP [Time frame: week 4]
- Change and percent change from baseline in LDL-C [Time frame: week 4]
Eligibility criteria
Inclusion criteria
- Patients with hypertension and dyslipidemia
Exclusion criteria
- The subject not meet the specified msBP and LDL-C level
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
South Korea · 1 center
- Gangdong Sacred Heart Hospital — Seoul
Identifiers
NCT: NCT06643130 · JW24301